Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176328 | 0.94 | AAK1 (0.71) | AAK1ROCK2 | |
| SCHEMBL20176332 | 0.94 | AAK1 (0.72) | AAK1ROCK2 | |
| SCHEMBL15240960 | 0.90 | AAK1 (0.57) | AAK1ROCK2 | |
| SCHEMBL15240957 | 0.90 | AAK1 (0.57) | AAK1ROCK2 | |
| SCHEMBL19946043 | 0.86 | AAK1 (0.76) | AAK1ROCK2 | |
| SCHEMBL20176322 | 0.85 | AAK1 (0.62) | AAK1ROCK2 | |
| SCHEMBL15251643 | 0.84 | AAK1 (0.65) | AAK1ROCK2 | |
| SCHEMBL15240914 | 0.84 | AAK1 (0.65) | AAK1ROCK2 | |
| SCHEMBL15250457 | 0.84 | AAK1 (0.58) | AAK1ROCK2 | |
| SCHEMBL15240912 | 0.84 | AAK1 (0.65) | AAK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292124-B1 | 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3292124-A2 | FUSED PYRIDINES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | AAK1 1/4885ROCK2 966/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885ROCK2 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.